DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Semapimod
Semapimod
Immunomodulation: a Broad Perspective for Patients' Survival of COVID-19 Infection
(12) Patent Application Publication (10) Pub. No.: US 2011/0224301 A1 ZAMORA Et Al
Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting Microglia
Stembook 2018.Pdf
Characterisation of Hmgb1 in Inflammation Characterisation of Hmgb1 in Inflammation
New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases
Severe Crohn's Disease Semapimod Induces Clinical Remission in Specific Inhibition of C-Raf Activity By
(12) United States Patent (10) Patent No.: US 8,314,149 B2 Zamora Et Al
Gut Inflammation: Current Update On
Blockade of Endogenous Proinflammatory Cytokines Ameliorates Endothelial Dysfunction in Obese Zucker Rats
An Inter-Species Translation Model Implicates Integrin Signaling in Infliximab-Resistant Colonic Crohn’S Disease
Inflammatory Bowel Disease: Exploring Gut Pathophysiology for Novel Therapeutic Targets
New Therapeutic Strategies for Treatment of Inflammatory Bowel Disease
Customs Tariff - Schedule Xxi - 1
Hypusine Modification of the Ribosome
Investigating the Central Role of Astrocytes in Mediating Postanesthetic Memory Deficits
Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone Gp96
JIA Guideline Appendix 4
Top View
KMU-1170, a Novel Multi-Protein Kinase Inhibitor, Suppresses
Tepzz 5 58¥Zb T
Curricular Track I—Immunomodulation in Rheumatology and Gastrointestinal Diseases Activity No
WO 2017/009712 Al 19 January 2017 (19.01.2017) P O P C T
Therapeutic Agents and Signal Transduction in Inflammatory Bowel Diseases
Drug Repurposing Opportunities for Inflammatory Bowel Disease
FORUM Annual Lecture: the Mind-Body Interface